Mindray Beats, Profit Up - Analyst Blog
07 Agosto 2012 - 11:00AM
Zacks
Chinese medical devices major
Mindray Medical International Limited’s (MR)
second-quarter 2012 adjusted (excluding one-time expenses other
than stock-based compensation expense) earnings per share of 45
cents beat the Zacks Consensus Estimate of 44 cents. Reported net
income moved up 16.1% year over year to $52 million (or 44 cents
per share) in the quarter.
Revenues
Revenues were up sharply 23.3% year
over year to $267.8 million, in the second quarter, beating the
Zacks Consensus Estimate of $258 million.
During the reported quarter,
Mindray recorded outside-China sales of $152.5 million, up 20.5%
year over year. Revenues in China increased 27.1% year over year to
$115.3 million in the reported quarter. The company performed well
in other emerging markets with growth of 21.1%.
Segment-wise
Revenues
Patient Monitoring & Life
Support Products (42.8% of total sales) sales grew 23.3% year over
year in the reported quarter to $114.6 million. In-Vitro Diagnostic
Products (27.6% of total revenue) revenues were $73.9 million, up
31.1%. Revenues from reagents contributed 34.4% of In-Vitro
Diagnostic segment sales during the quarter.
Medical Imaging Systems (24% of
total sales) sales rose to $64.1 million, a growth of 15.1%. Other
revenues (5.6% of total revenue) were up 24.4% to $15.1
million.
Margins
Adjusted gross profit amounted to
$154.8 million in the quarter, higher 23.7% year over year.
Adjusted gross margin was 57.8% slightly higher than 57.6% in the
year-ago period.
Adjusted selling expenses were
$45.5 million, or 17% of total net sales, compared with 17.7% a
year ago. Adjusted general and administrative expenses were $23.3
million, or 8.7% of sales, versus 7.7% a year ago. Adjusted
research and development expenses were $22.5 million, or 8.4% of
sales, compared with 8% in the prior-year quarter.
Adjusted operating income stood at
$63.5 million in the quarter, a year-over-year growth of 20.9%.
Adjusted operating margin was 23.7%, lower than 24.2% in the
year-ago quarter.
Balance Sheet and Cash
Flow
As of June 30, 2012, Mindray had
$710.1 million in cash and liquid investments, up about 52% from
the year ago. Long-term bank loan stood at $85.1 million, up 143.3%
from a year ago. Net cash generated from operating activities was
$61.4 million in the quarter (up 81.6% year over year) while
capital expenditure amounted to $16.7 million.
Outlook
Mindray provides guidance on a full
year basis. The company continues to forecast sales growth in
excess of 18% for 2012. It also expects adjusted net income for the
year to increase by a minimum of 15% year over year (a minimum of
13% earlier). The guidance does not take into account any tax
advantage on account of key software enterprise status. The
forecast for capital expenditure for fiscal 2012 is about $90
million.
Mindray is a bellwether in the
Chinese MedTech industry with a solid international presence. A key
distinction with domestic competitors is that the majority of
Mindray’s products have CE Mark and/or Food and Drug Administration
(FDA) clearance.
Mindray maintains a decent product
pipeline and brings out several new products each year. New
products contribute in a major way to Mindray’s revenues. In fiscal
2011, the company launched 13 new products.
The company has entered the premium
segment globally, where its competitive advantage is still unclear.
Also, on the negative side, health care reform in China and the
U.S. may reduce demand for Mindray’s products. Competition is
fierce and leads to price erosion over time.
Mindray’s competitors, in different
niche segments, include GE Healthcare, a part of General
Electric (GE), Philips (PHG) and
Siemens (SI). Our Neutral recommendation is
supported by a short-term Zacks #3 Rank (Hold).
GENL ELECTRIC (GE): Free Stock Analysis Report
MINDRAY MEDICAL (MR): Free Stock Analysis Report
KONINKLIJKE PHL (PHG): Free Stock Analysis Report
SIEMENS AG-ADR (SI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Lug 2023 a Lug 2024